SPAC6G9.05 Antibody

What is SPAC6G9.05 and why is it important in research?

SPAC6G9.05 is a gene/protein identifier in the fission yeast Schizosaccharomyces pombe genome. Similar to other SPAC-prefixed genes like SPBC1D7.05 and SPBC24C6.06, it follows the standard Pombase nomenclature for fission yeast genes . Understanding SPAC6G9.05 is valuable for researchers investigating fundamental cellular processes in eukaryotic systems. Like other fission yeast proteins that function in signaling pathways, cell morphogenesis, and conjugation regulation, SPAC6G9.05 likely plays specific roles in cellular mechanisms that can be elucidated through antibody-based detection methods . Targeted antibodies against this protein enable researchers to investigate its expression, localization, and functional interactions within cellular contexts.

How do antibodies against yeast proteins like SPAC6G9.05 differ from conventional mammalian antibodies?

Antibodies against yeast proteins require specific considerations that differ from mammalian antibody development. Unlike mammalian targets where commercially available antibodies often show cross-reactivity across species (e.g., mouse to human), yeast proteins like SPAC6G9.05 may require highly specific antibodies with minimal cross-reactivity to other fungal proteins . The specificity profile differs significantly - for example, while antibodies like RMG05 are designed to react with specific immunoglobulin regions across multiple IgG subtypes (IgG1, IgG2a, IgG2b, IgG3), antibodies against yeast proteins typically target unique epitopes with minimal conservation across species . Additionally, the applications often differ, with yeast protein antibodies being particularly valuable for chromatin immunoprecipitation, subcellular localization studies, and protein-protein interaction assays in fundamental cell biology research.

What are the fundamental properties to consider when selecting an antibody for SPAC6G9.05 detection?

When selecting an antibody for SPAC6G9.05 detection, researchers should consider multiple critical properties:

• Specificity: The antibody should recognize SPAC6G9.05 with minimal cross-reactivity to related yeast proteins, especially those with similar domains or structures. Rigorous validation through Western blotting against both recombinant protein and yeast lysates is essential.

• Epitope recognition: Consider whether the antibody recognizes native or denatured forms of the protein, as this determines suitable applications (immunoprecipitation vs. Western blotting) .

• Clonality: Monoclonal antibodies provide consistent results across experiments with high specificity, while polyclonal antibodies offer broader epitope recognition . For novel targets like SPAC6G9.05, polyclonals may be initially advantageous.

• Host species: Consider the host species to avoid cross-reactivity in multi-labeling experiments. Antibodies produced in goats, like the reference RMG05, provide advantages when working with mouse or rabbit secondary detection systems .

• Storage and stability: Antibody formulations with stabilizers like 50% glycerol/PBS with BSA typically offer better long-term performance, similar to the storage conditions used for the reference antibody (stable for 1 year at -20°C) .

How should I design validation experiments for a new SPAC6G9.05 antibody?

Designing validation experiments for a new SPAC6G9.05 antibody requires a systematic approach that addresses specificity, sensitivity, and reproducibility. Begin with Western blot analysis using wild-type yeast lysates alongside lysates from SPAC6G9.05 deletion strains as negative controls. This establishes specificity by confirming the absence of signal in knockout samples. Next, perform immunoprecipitation followed by mass spectrometry to verify that the antibody pulls down SPAC6G9.05 and identify potential interacting partners.

For immunolocalization validation, compare antibody staining patterns with GFP-tagged SPAC6G9.05 expressed at endogenous levels. Additionally, conduct epitope mapping to identify the exact binding region, which helps predict potential cross-reactivity with homologous proteins. Similar to the protein interaction assay described in the literature, co-expression of tagged versions (such as HA-tagged SPAC6G9.05) can be used to confirm antibody specificity through Western blot analysis .

A titration experiment similar to those performed for other antibodies should be conducted, where plates are coated with recombinant SPAC6G9.05 at varying concentrations (50-500 ng/well) and antibody dilutions from 1:100 to 1:10,000 are tested to establish optimal working concentrations for different applications .

What is the optimal protein extraction protocol for detecting SPAC6G9.05 in fission yeast?

The optimal protein extraction protocol for SPAC6G9.05 detection should preserve protein integrity while maximizing yield. Based on established protocols for similar yeast proteins, I recommend the following methodology:

• Cell harvest and preparation: Culture fission yeast to mid-log phase (OD600 of 0.4-0.8). Harvest cells by centrifugation at 3,000 × g for 5 minutes at 4°C.

• Cell lysis buffer: Resuspend cells in extraction buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM EDTA, 2 mM EGTA, 150-200 mM NaCl, 1% Triton X-100, and 1 mM PMSF as a protease inhibitor . For membrane-associated proteins, consider adding 0.1% SDS or increasing detergent concentration.

• Mechanical disruption: Lyse cells using glass beads in a bead-beater with cooling cycles to prevent protein denaturation. Perform 6-8 cycles of 30 seconds beating followed by 30 seconds on ice.

• Clarification: Centrifuge the lysate at 13,000 × g for 20 minutes at 4°C to separate soluble proteins from cell debris . For membrane proteins, an ultracentrifugation step (100,000 × g) may be necessary.

• Storage: Add glycerol to a final concentration of 20% for storage at -80°C . Avoid repeated freeze-thaw cycles.

This protocol has been successfully applied to extract proteins like Spo7 from fission yeast and should be effective for SPAC6G9.05 extraction while maintaining antibody epitope accessibility .

How can I establish the working dilution range for a SPAC6G9.05 antibody across different applications?

Establishing the optimal working dilution range for a SPAC6G9.05 antibody requires systematic titration across different applications. For each application, follow these methodological approaches:

For Western blotting, prepare a dilution series (1:500, 1:1000, 1:2000, 1:5000, 1:10000) of the primary antibody and test against standardized amounts of yeast lysate (20-50 μg/lane). Evaluate signal-to-noise ratio at each dilution, noting the lowest concentration that provides clear, specific bands with minimal background.

For immunofluorescence, test a narrower range starting with higher concentrations (1:100, 1:200, 1:500, 1:1000) against fixed yeast cells. Compare specific staining versus background at each dilution, considering counterstaining with DAPI to evaluate nuclear localization if expected.

For ELISA applications, establish a standard curve similar to the approach used with the RMG05 antibody . Coat plates with recombinant SPAC6G9.05 protein at different concentrations (10-100 ng/well) and test antibody dilutions from 0.05 μg/mL to 1 μg/mL. This allows you to determine both sensitivity and optimal concentration ranges .

This data can be organized in a reference table:

Document batch-to-batch variation by retaining reference samples of working antibody dilutions to ensure reproducibility across experiments.

How can I optimize immunoprecipitation experiments with SPAC6G9.05 antibodies?

Optimizing immunoprecipitation (IP) experiments with SPAC6G9.05 antibodies requires careful attention to multiple parameters. Begin by determining the antibody's binding characteristics - for instance, whether it recognizes native or denatured epitopes, which influences buffer composition. For standard IP protocols with SPAC6G9.05, adapt the approach used for similar yeast proteins:

• Pre-clearing step: Incubate cell lysates (prepared in extraction buffer as described earlier) with protein G Sepharose beads for 1 hour at 4°C to reduce non-specific binding .

• Antibody binding: Add 2-5 μg of SPAC6G9.05 antibody to 500-1000 μg of pre-cleared lysate and incubate at 4°C for 2-4 hours on a rotating platform. For the negative control, use non-specific IgG from the same species as the SPAC6G9.05 antibody.

• Immunoprecipitation: Add 40 μl of protein G Sepharose beads (pre-equilibrated in extraction buffer) and incubate overnight at 4°C with gentle rotation .

• Washing: Perform 4-6 sequential washes with decreasing salt concentration buffers, starting with high stringency (500 mM NaCl) and ending with low stringency (150 mM NaCl) to remove non-specifically bound proteins .

• Elution optimization: For mass spectrometry applications, elute with 0.1 M glycine (pH 2.5) or SDS sample buffer. For co-IP experiments to maintain protein-protein interactions, use gentler elution conditions.

Cross-linking the antibody to beads with dimethyl pimelimidate can prevent antibody co-elution, important when detecting proteins of similar molecular weight to antibody chains. Document the efficiency of your IP by analyzing both the immunoprecipitated fraction and unbound supernatant by Western blotting .

What chromatin immunoprecipitation (ChIP) protocol modifications are needed for SPAC6G9.05 antibodies?

Chromatin immunoprecipitation (ChIP) with SPAC6G9.05 antibodies requires specific protocol modifications to account for the unique challenges of yeast cells and potential nuclear localization of the target protein:

• Cell fixation optimization: For fission yeast, use 1% formaldehyde for a shorter duration (10-15 minutes) compared to mammalian protocols due to the different cell wall composition. Quench with 125 mM glycine for 5 minutes.

• Cell wall disruption: Unlike mammalian ChIP, enzymatic digestion of the yeast cell wall is critical. Pretreat cells with Zymolyase (1 mg/ml) for 30 minutes at 30°C before mechanical disruption with glass beads.

• Chromatin shearing: Sonicate using a Bioruptor or similar device with optimized conditions (typically 25-30 cycles of 30 seconds on/30 seconds off) to achieve fragments of 200-500 bp. Verify fragment size by agarose gel electrophoresis.

• Antibody specificity controls: Include both negative controls (non-specific IgG, untagged strains) and positive controls (if available, strains with epitope-tagged SPAC6G9.05). This is especially important when using newly developed antibodies against yeast proteins.

• Protein-DNA complex isolation: Increase incubation time with the SPAC6G9.05 antibody to 4-6 hours at 4°C, followed by overnight incubation with protein G beads to maximize recovery of specific complexes.

• Washing stringency adjustment: Include at least one high-salt wash (500 mM NaCl) and one LiCl wash (250 mM LiCl) to reduce non-specific DNA binding, which is particularly important for fission yeast samples.

• Cross-link reversal and DNA purification: Perform reversal at 65°C for 6 hours, followed by RNase and Proteinase K treatment. Purify DNA using phenol-chloroform extraction or commercially available kits optimized for small DNA fragments.

This modified protocol addresses the unique challenges of performing ChIP with antibodies against fission yeast proteins while maximizing signal-to-noise ratio.

How can I use protein-lipid overlay assays to investigate SPAC6G9.05 interactions with cellular membranes?

Protein-lipid overlay assays provide valuable insights into potential membrane interactions of SPAC6G9.05. If SPAC6G9.05 contains domains similar to pleckstrin homology (PH) domains found in proteins like Spo7, these assays can reveal specific lipid-binding properties . The methodology should be adapted as follows:

• Recombinant protein expression: Clone the full-length SPAC6G9.05 or relevant domains (predicted lipid-binding regions) into a GST expression vector. Transform into E. coli BL21 and induce expression with 100 μM IPTG at 30°C for 4 hours when cultures reach OD600 of 0.4-0.5 .

• Protein purification: Harvest cells and lyse in Buffer A (10 mM Tris-HCl, pH 7.4, 1 M NaCl, 1% Triton X-100, 1 mM DTT, 0.5 mM PMSF). Purify using glutathione-Sepharose beads with extensive washing, followed by elution with Buffer B containing 20 mM glutathione .

• Membrane strip preparation: Commercial lipid strips containing 15 different biologically relevant lipids spotted onto nitrocellulose membranes can be used. Alternatively, prepare custom strips with specific lipids of interest, such as phosphoinositides that often interact with PH domains.

• Binding assay: Block the membrane in 3% fatty acid-free BSA in TBST. Incubate with purified GST-SPAC6G9.05 protein (1-5 μg/ml) overnight at 4°C. Include a GST-only control to identify non-specific binding .

• Detection: Wash extensively with TBST and detect bound protein using anti-GST antibodies or, if the fusion protein contains other tags, appropriate detection antibodies.

• Quantification: Analyze spot intensity using densitometry software to determine relative binding affinities for different lipids.

This assay can reveal whether SPAC6G9.05 preferentially binds to specific phospholipids, suggesting potential roles in membrane targeting or regulation of membrane-associated processes, similar to other SPB components in fission yeast .

What are common causes of non-specific binding when using SPAC6G9.05 antibodies, and how can they be addressed?

Non-specific binding with SPAC6G9.05 antibodies can manifest as multiple unexpected bands in Western blots or diffuse staining in immunofluorescence. These issues have several potential causes and solutions:

• Cross-reactivity with related proteins: Fission yeast contains numerous proteins with similar domains that may share epitopes with SPAC6G9.05. Increase antibody specificity by:

  • Pre-adsorbing the antibody with lysates from SPAC6G9.05 deletion strains

  • Using affinity-purified antibodies against specific peptide regions rather than whole protein immunogens

  • Increasing washing stringency with higher salt concentrations (up to 500 mM NaCl) in TBST

• Inadequate blocking: Insufficient blocking leads to high background. Optimize by:

  • Testing different blocking agents (5% non-fat milk, 3-5% BSA, commercial blockers)

  • Extending blocking time to 2 hours at room temperature or overnight at 4°C

  • Using 1% BSA in blocking buffer for phospho-specific applications

• Suboptimal antibody concentration: Too high antibody concentrations often increase non-specific binding. Create a dilution series to identify the minimum concentration that yields specific signal, typically starting with the range of 0.05-1 μg/ml as established for similar antibodies .

• Detection system issues: Secondary antibody cross-reactivity can be addressed by:

  • Using secondary antibodies pre-adsorbed against yeast proteins

  • Including 0.1% Triton X-100 in wash buffers to reduce hydrophobic interactions

  • Selecting secondary antibodies with minimal species cross-reactivity

• Sample preparation problems: Degraded samples can produce multiple bands. Prevent by:

  • Adding protease inhibitor cocktails to all extraction buffers

  • Maintaining samples at 4°C throughout processing

  • Avoiding repeated freeze-thaw cycles by storing in 20% glycerol at -80°C

Document optimization steps in a troubleshooting log to track improvements and establish reproducible protocols for your specific experimental system.

How should I interpret contradictory localization data between antibody-based and GFP-fusion approaches for SPAC6G9.05?

Contradictory localization data between antibody-based detection and GFP-fusion approaches for SPAC6G9.05 requires systematic analysis to resolve discrepancies. This is a common challenge in protein localization studies that can stem from multiple factors:

• Epitope masking: The antibody's epitope may be inaccessible in certain subcellular compartments due to protein-protein interactions or conformational changes. To address this:

  • Generate antibodies against multiple regions of SPAC6G9.05

  • Test different fixation methods (paraformaldehyde, methanol, acetone) that may preserve different epitopes

  • Compare with antibodies against different epitopes if available

• GFP-fusion artifacts: The GFP tag (27 kDa) may disrupt normal localization or function of SPAC6G9.05. Evaluate this possibility by:

  • Testing both N-terminal and C-terminal fusions

  • Creating internal GFP fusions if terminal tagging affects function

  • Verifying that GFP-tagged proteins complement SPAC6G9.05 deletion phenotypes

  • Comparing expression levels of tagged proteins to endogenous levels

• Methodological differences: Different preparation methods can yield different results:

  • For membrane-associated proteins, detergent extraction conditions significantly impact localization

  • Live cell imaging (GFP) versus fixed cell immunostaining may reveal different aspects of dynamic localization

  • Antibody accessibility may be limited in certain cellular compartments

• Temporal dynamics: The protein may relocalize during the cell cycle or in response to specific stimuli. To address this:

  • Perform time-course experiments with synchronized cultures

  • Compare localization under different growth conditions or stresses

  • Use dual-labeling approaches with cell cycle markers

When presenting contradictory data, document both approaches with their respective controls and consider that both may reveal valid but different aspects of SPAC6G9.05 biology. The complementary use of both techniques often provides the most complete understanding of protein localization and function.

What statistical approaches are appropriate for quantifying SPAC6G9.05 expression levels across different growth conditions?

• Experimental design considerations:

  • Include at least 3-5 biological replicates per condition

  • Incorporate technical replicates (2-3 per biological sample) to assess measurement variability

  • Include appropriate housekeeping controls (e.g., Act1, Cdc2) known to maintain stable expression across your tested conditions

  • Design time course experiments with sufficient temporal resolution to capture expression dynamics

• Normalization strategies:

  • For Western blot quantification, normalize SPAC6G9.05 band intensity to total protein (measured by Ponceau S staining) rather than single housekeeping proteins

  • For qPCR, use the geometric mean of multiple reference genes rather than a single control

  • Apply global normalization methods for proteomics or transcriptomics datasets

• Statistical analysis methods:

  • For comparing two conditions: paired t-test if samples are matched, unpaired t-test if independent

  • For multiple conditions: one-way ANOVA followed by appropriate post-hoc tests (Tukey's HSD for all pairwise comparisons or Dunnett's test for comparing all conditions to a control)

  • For time course data: repeated measures ANOVA or mixed-effects models

  • For non-normally distributed data: non-parametric alternatives (Mann-Whitney, Kruskal-Wallis)

• Data visualization:

  • Present individual data points alongside means and standard deviations/standard errors

  • For time course data, use line graphs with error bars

  • For multiple condition comparisons, use bar graphs with significance indicators

• Effect size estimation:

  • Report fold changes with confidence intervals

  • Calculate Cohen's d or similar effect size metrics to quantify the magnitude of differences

  • Determine the minimum sample size needed for adequate statistical power (typically aiming for 80% power)

When presenting results, provide comprehensive statistical details including test selection rationale, p-values, sample sizes, and effect sizes. This transparency ensures reproducibility and proper interpretation of expression changes across conditions.

How can phospho-specific antibodies against SPAC6G9.05 be developed and validated?

Developing phospho-specific antibodies against SPAC6G9.05 requires a specialized approach that differs from standard antibody production. This advanced technique enables researchers to track specific phosphorylation events that may regulate SPAC6G9.05 function:

• Phosphorylation site identification: First, identify potential phosphorylation sites through:

  • Bioinformatic prediction using tools like NetPhos, GPS, or PhosphoSitePlus

  • Mass spectrometry analysis of immunoprecipitated SPAC6G9.05 from yeast lysates

  • Comparison with known phosphorylation sites in homologous proteins

• Phosphopeptide design: For each target phosphorylation site, design a phosphopeptide immunogen:

  • Include the phosphorylated residue centrally within a 10-15 amino acid sequence

  • Ensure peptide uniqueness through BLAST analysis against the S. pombe proteome

  • Add a C-terminal cysteine for conjugation to carrier protein (KLH or BSA)

  • Prepare both phosphorylated and non-phosphorylated versions of each peptide

• Immunization and antibody production:

  • Immunize rabbits or other suitable host animals with the phosphopeptide conjugate

  • Collect serum and perform initial ELISA screening against phospho and non-phospho peptides

• Dual purification strategy:

  • First, affinity-purify antibodies using the phosphopeptide column

  • Second, perform negative selection using a non-phosphopeptide column to remove antibodies that recognize the non-phosphorylated sequence

  • Elute and collect only the highly specific phospho-directed antibodies

• Validation approaches:

  • Western blot comparison of wild-type lysates versus samples treated with phosphatase

  • Testing against lysates from yeast strains with phosphomimetic (S/T→D/E) or phosphodeficient (S/T→A) mutations at the target site

  • Induction of phosphorylation through relevant stimuli or cell cycle stages

  • Mass spectrometry confirmation of immunoprecipitated proteins

• Specificity controls:

  • Peptide competition assays with phospho and non-phospho peptides

  • Analysis of signal in kinase knockout strains that target the specific site

  • Comparison of signal across multiple techniques (Western blot, immunofluorescence)

This methodological approach ensures development of highly specific phospho-antibodies that can reveal important regulatory mechanisms controlling SPAC6G9.05 function in response to cellular signaling events.

What approaches can resolve contradictory biochemical data about SPAC6G9.05 multiprotein complexes?

Resolving contradictory biochemical data about SPAC6G9.05 multiprotein complexes requires integrated methodological approaches that address the limitations of individual techniques:

• Orthogonal interaction verification:

  • Compare results from reciprocal co-immunoprecipitation experiments using antibodies against different complex components

  • Validate interactions using alternative methods like yeast two-hybrid, proximity labeling (BioID), or FRET/FLIM

  • Apply quantitative mass spectrometry approaches (SILAC, TMT) to distinguish specific from non-specific interactions

• Interaction dynamics assessment:

  • Evaluate complex formation across different growth conditions, cell cycle stages, or stress responses

  • Use crosslinking mass spectrometry (XL-MS) to capture transient interactions

  • Employ size exclusion chromatography with multi-angle light scattering (SEC-MALS) to determine complex stoichiometry and heterogeneity

• Functional validation of interactions:

  • Generate point mutations that specifically disrupt individual interactions without affecting protein stability

  • Perform genetic interaction studies (synthetic lethality/sickness) between complex components

  • Assess phenotypic consequences of disrupting specific interactions

• Structural approaches:

  • Use cryo-electron microscopy for larger complexes or X-ray crystallography for smaller subcomplexes

  • Apply integrative structural biology combining multiple data types (SAXS, NMR, computational modeling)

  • Identify interaction interfaces through hydrogen-deuterium exchange mass spectrometry

• Contextual analysis:

  • Consider cellular compartmentalization through fractionation studies

  • Evaluate post-translational modifications that may regulate interactions

  • Assess competition between different interaction partners through in vitro reconstitution

When presenting contradictory data, organize findings in a comprehensive comparison table:

This systematic approach acknowledges that different techniques reveal different aspects of complex biology, and integration of multiple methods provides the most complete understanding of SPAC6G9.05 interaction networks.

How can CRISPR-Cas9 genome editing be optimized for studying SPAC6G9.05 function in combination with antibody-based detection?

CRISPR-Cas9 genome editing offers powerful approaches for studying SPAC6G9.05 function when combined with antibody-based detection methods. Optimizing this integrated methodology requires careful consideration of multiple factors:

• Strategic modification design:

  • For epitope tagging: Insert small epitope tags (FLAG, HA, V5) that have well-characterized, highly specific commercial antibodies

  • For endogenous tagging: Place tags at positions verified not to disrupt protein function through complementation testing

  • For domain analysis: Design precise deletions or mutations of specific domains while maintaining reading frame

  • For regulatory studies: Edit specific phosphorylation sites or other post-translational modification sites

• CRISPR-Cas9 optimization for S. pombe:

  • Select guide RNAs with high specificity scores and minimal off-target potential using S. pombe-specific prediction tools

  • Use ribonucleoprotein (RNP) delivery rather than plasmid expression to reduce off-target effects

  • Incorporate homology-directed repair templates with at least 50 bp homology arms on each side

  • Include selection markers (antibiotic resistance) flanked by LoxP sites for marker removal after verification

• Validation strategy:

  • Sequence verify all modifications at the genomic level

  • Confirm protein expression and modification using the selected antibodies

  • Verify protein functionality through phenotypic analysis compared to wild-type

  • Check for potential off-target effects by sequencing predicted off-target sites

• Combined analytical approaches:

  • ChIP-seq: Use anti-tag antibodies for chromatin immunoprecipitation followed by sequencing to map genome-wide binding sites

  • Proximity labeling: Fuse BioID or APEX2 to SPAC6G9.05 to identify neighboring proteins in specific cellular compartments

  • FRAP (Fluorescence Recovery After Photobleaching): Combine fluorescent tagging with live-cell microscopy to analyze protein dynamics

  • Functional genomics: Create libraries of SPAC6G9.05 variants with systematic mutations for structure-function analysis

• Multiplexed editing strategies:

  • Generate double or triple edits to study genetic interactions

  • Create conditional alleles using auxin-inducible degron tags for temporal control

  • Implement orthogonal tagging strategies for simultaneous tracking of multiple proteins

This integrated approach combines the precision of CRISPR-Cas9 editing with the analytical power of antibody-based detection methods, enabling comprehensive functional analysis of SPAC6G9.05 across multiple experimental contexts and cellular conditions.